Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

作者：Michael Aboud, Richard Kaplan, Johannes Lombaard, Fujie Zhang, José A. Hidalgo, Elmira Mamedova, Marcelo Losso, Ploenchan Chetchotisakd, Carlos Brites, Jörg Sievers, Dannae Brown, Judy Hopking, Mark Underwood, Maria Cláudia Nascimento, Yogesh Punekar, Martin Gartland, Kimberly Y. Smith · 发表于：The Lancet Infectious Diseases · 年份：2019 · DOI：10.1016/s1473-3099(19)30036-2 · 被引用次数：198 · 研究领域：HIV/AIDS drug development and treatment、HIV-related health complications and treatments、HIV Research and Treatment